Southeast Retina Center

Running trials

• Not yet recruiting

  Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.

  NCT07864480· Phase 4· Source

• Recruiting

  A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

  NCT07215390· Phase 2· Source

• Active, not recruiting

  4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

  NCT06864988· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

  NCT06770933· Phase 2· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

  NCT06495918· Phase 3· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK

  NCT06556368· Phase 3· Source

• Active, not recruiting

  Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT05769153· Phase 1/2· Source

• Active, not recruiting

  Evaluation of Tonabersat for DME

  NCT05727891· Phase 2· Source

• Active, not recruiting

  An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

  NCT05300724· Source

• Active, not recruiting

  A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

  NCT04853251· Phase 4· Source

• Active, not recruiting

  A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

  NCT04108156· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration2 recruiting
• Diabetic eye disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT06961370· Phase 1· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

  NCT06270836· Phase 3· Source

• Completed

  Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

  NCT06116890· Phase 2· Source

• Completed

  Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

  NCT05891548· Phase 2· Source

• Completed

  A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

  NCT05839041· Phase 2· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Source

• Completed

  A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

  NCT05066997· Phase 2/3· Source

• Completed

  A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

  NCT04740671· Phase 3· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Source

• Completed

  Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

  NCT04567303· Phase 1/2· Source

• Terminated

  HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04566445· Phase 2· Source

• Completed

  A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Phase 3· Source

• Completed

  A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

  NCT04527107· Phase 2· Source

• Terminated

  EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

  NCT04437368· Phase 2· Source

• Terminated

  GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

  NCT03894020· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Source